全球神经营养性角膜炎治疗市场规模（按治疗、地区、范围和预测）

神经营养性角膜炎治疗市场规模及预测

神经营养性角膜炎治疗市场规模预计在 2023 年达到 44 亿美元，到 2030 年将达到 88.1 亿美元，2024 年至 2030 年的复合年增长率为 7.2%。

全球神经营养性角膜炎治疗市场的市场推动因素

神经营养性角膜炎治疗市场的市场推动因素可能受到多种因素的影响。

神经营养性角膜炎发生率不断上升：一个重要因素是神经营养性角膜炎发生率不断上升，其发病原因包括糖尿病、带状疱疹、术后困难等，常与疾病相关。人口老化也是导致盛行率上升的原因之一，因为老年人更容易患上这些潜在疾病。

诊断进展：

诊断技术的进步使得能够早期准确地识别神经营养性角膜炎，增加了对治疗方案的需求。生物标誌物的发现和影像技术的改进有助于改善疾病管理。

创造创新治疗方法：

由于重组人类神经生长因子（cenegermin）等新型治疗剂和尖端治疗方法的发展，市场正在不断扩大。这些创新治疗方法更具针对性和更有效，可能会改善患者的治疗效果。

提高知识和敏感度：

随着患者和医疗保健专业人员对神经营养性角膜炎及其可用治疗方法的瞭解不断增加，市场正在扩大。教育工作和越来越多的研究论文正在提高人们对该疾病的认识和理解。

科学技术研究补助金：

新疗法的发现得益于製药公司和学术机构对研发的大量投资。这带来了大量潜在治疗方法，促进了市场扩张。

监理机关的批准与支持：

良好的监管环境有利于市场扩张，FDA 和 EMA 批准了新疗法。此外，对于加速审查程序和孤儿药指定的监管支援也很有利。

创新：

药物传递技术的发展，例如缓释製剂和基于奈米技术的方法，正在提高治疗神经营养性角膜炎的便利性和有效性，有助于扩大市场。

医疗费用不断增加：

政府和企业对医疗保健的资助提高了获得尖端神经营养性角膜炎治疗的机会。此外，报销指南的改善和医疗保健基础设施的发展也在推动市场扩张。

增加微创手术的使用：

对于侵入性较小、恢復时间较短、併发症风险较低的治疗的需求正在对市场产生积极影响。使用这些技术治疗神经营养性角膜炎正在获得认可。

合作伙伴关係和协作：神经营养性角膜炎治疗的创新由研究机构、製药公司和医疗保健提供者之间的策略联盟和伙伴关係推动。这类合作的目标通常是为了加速新疗法的发现和行销。

限制全球神经营养性角膜炎治疗市场的因素

有几个因素可能会对神经营养性角膜炎治疗市场造成市场限制和课题。这些包括：

高昂的医疗费用：

手术和重组人类神经生长因子 (rhNGF) 等最先进的治疗方法对于治疗神经营养性角膜炎的费用非常昂贵。患者可能会发现难以获得这种治疗，特别是在没有全民健保的地区。

知识与诊断不足：

由于神经营养性角膜炎是一种罕见疾病，患者和医护人员往往缺乏对它的知识。这可能会导致误诊或漏诊，减少接受适当治疗的患者数量。

监理课题：

获得监管机构批准的新疗法成本高且耗时。由于 FDA 和 EMA 等组织实施的严格监管，新疗法进入市场可能需要一些时间。

替代疗法的可用性：

更多平价的替代品（如传统眼药水、药膏和自体血清眼药水）的出现，可能会减少对更昂贵和更先进的治疗的需求。某些医疗专业人士和患者可能会更喜欢这些较便宜的选择。

安全性问题与副作用：

由于不良副作用，患者可能会拒绝接受某些 NK 疗法。在获得长期安全性和有效性的证据之前，安全问题可能会阻碍新疗法的采用。

保险和报销问题：

NK 治疗的保险覆盖范围各不相同，有些治疗根本不包括在内。这可能会导致患者自付费用增加，并进一步限制获得有效治疗的机会。

有限的研究与发展：

与更常见的疾病相比，这种疾病的罕见性意味着正在进行的研究和开发相对较少。这可能会阻碍新疗法的开发和现有疗法的进展。

经济阻碍因素：

在中低收入国家，财政限制会严重限制人们获得尖端 NK 治疗的机会。这些地区的医疗保健基础设施不足可能会阻碍先进药物的广泛普及和使用。

病人依从性：

NK 治疗通常需要严格遵守药物治疗，这对患者来说可能很困难。缺乏依从性可能导致治疗结果不理想且治疗效果被低估。

缺乏专业照护：

神经营养性角膜炎的治疗通常需要有治疗角膜疾病经验的眼科医师的服务。专家的短缺是提供优质医疗服务的一大障碍，尤其是在贫困的农村地区。

目录

第 1 章全球神经营养性角膜炎治疗市场简介

市场概况
• 研究范围
• 先决条件

第 2 章执行摘要

第 3 章：经过验证的市场研究方法

• 资料探勘
• 验证
• 第一次面试
• 资料来源列表

第 4 章全球神经营养性角膜炎治疗市场展望

• 概述
• 市场动态
  • 驱动程式
  • 阻碍因素
  • 机会
• 波特五力模型
• 价值链分析

第5章 神经营养性角膜炎治疗的全球市场（按疗法）

• 外用抗生素
• 重组人类神经生长因子（rhNGF）
• 羊膜移植
• 角膜移植手术
• 其他

第6章 全球神经营养性角膜炎治疗市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
  亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 世界其他地区
  • 拉丁美洲
  • 中东和非洲

第 7 章全球神经营养性角膜炎治疗市场的竞争格局

• 概述
• 各公司的市场排名
• 主要发展策略

第 8 章 公司简介

• Santen Pharmaceutical Co. Ltd.
• Novartis AG
• RegeneRx
• Biopharmaceuticals Inc.
• Dompe farmaceutici S.p.A.
• Dompe Farma S.r.l.
• Horizon Therapeutics plc
• AuroLab
• Genentech Inc.（a subsidiary of Roche Holding AG）
• Johnson & Johnson Services Inc.
• Allergan（a subsidiary of AbbVie Inc.）

第9章 附录

• 关联调查

Neurotrophic Keratitis Treatment Market Size And Forecast

Neurotrophic Keratitis Treatment Market size was valued at USD 4.4 Billion in 2023 and is projected to reach USD 8.81 Billion by 2030, growing at a CAGR of 7.2% from 2024 to 2030.

Global Neurotrophic Keratitis Treatment Market Drivers

The market drivers for the Neurotrophic Keratitis Treatment Market can be influenced by various factors. These may include: Rising Neurotrophic Keratitis Prevalence: One important factor is the increasing prevalence of neurotrophic keratitis, which is frequently linked to diseases including diabetes, herpes zoster, and difficulties following surgery. Because older people are more susceptible to these underlying illnesses, an ageing population also plays a role in the rising prevalence.

Progress in Diagnostic Methods:

The need for treatment options is increasing due to advancements in diagnostic techniques that enable early and accurate identification of neurotrophic keratitis. Improved biomarker discovery and imaging technologies are contributing to improved disease management.

Creation of Innovative Treatments:

The market is growing due to the development of novel therapeutic drugs and cutting-edge treatments such recombinant human nerve growth factor (cenegermin). Better patient outcomes are possible thanks to these innovative treatments, which offer more focused and efficient methods.

Enhanced Knowledge and Sensitization:

The market is expanding as a result of patients' and healthcare professionals' increasing knowledge of neurotrophic keratitis and available treatments. More awareness and comprehension of the illness are being fostered by educational initiatives and an increase in research publications.

Expenditure on Scientific and Technological Research:

The identification of new treatment modalities is being facilitated by large investments made in research and development by pharmaceutical corporations and academic institutions. This is creating a strong pipeline of possible treatments and driving market expansion.

Regulatory Acceptance and Assistance:

Market expansion is being aided by favourable regulatory environments and the FDA and EMA approving novel therapies. Accelerated review procedures and regulatory assistance for orphan drug status are also advantageous.

Innovations in Technology:

Technological developments in medication delivery, like sustained-release formulations and nanotechnology-based methods, are improving the convenience and effectiveness of treatments for neurotrophic keratitis, which is propelling the market's expansion.

Increasing Costs of Healthcare:

Government and business sector funding on healthcare is improving access to cutting-edge neurotrophic keratitis treatments. Further fostering market expansion are better reimbursement guidelines and healthcare infrastructure.

Expanding Use of Procedures With Minimal Invasiveness:

The market is being positively impacted by the desire for less intrusive treatment choices that have shorter recovery times and a lower risk of consequences. The use of these techniques to treat neurotrophic keratitis is growing in acceptance.

Partnerships & Cooperations: Innovation in neurotrophic keratitis treatments is being propelled by strategic alliances and partnerships among research organisations, pharmaceutical businesses, and healthcare providers. The goal of these partnerships is frequently to hasten the creation and marketing of novel treatments.

Global Neurotrophic Keratitis Treatment Market Restraints

Several factors can act as restraints or challenges for the Neurotrophic Keratitis Treatment Market. These may include:

Exorbitant Treatment Costs:

Surgical procedures and cutting-edge therapy options, such as recombinant human nerve growth factor (rhNGF), can be highly costly for treating neurotrophic keratitis. Patients may find this to be less accessible, particularly in areas without universal healthcare.

Insufficient Knowledge and Diagnosis:

Since neurotrophic keratitis is an uncommon condition, both patients and medical professionals frequently lack knowledge about it. This may result in an incorrect or underdiagnosis, which would decrease the number of patients receiving the right care.

Regulatory Difficulties:

Getting novel treatments approved by the authorities can be an expensive and time-consuming procedure. New treatments may take longer to reach the market due to the strict regulations imposed by organisations like the FDA and EMA.

Availability of Alternative therapies:

The demand for more expensive, more advanced therapies may decline if there are more affordable alternatives available, such as traditional eye drops, ointments, and autologous serum eye drops. These less expensive options may be preferred by certain healthcare professionals and patients.

Safety concerns and adverse effects:

Patients may be discouraged from taking certain NK therapies because to their unpleasant side effects. Adoption of novel therapies may be hindered by safety concerns until long-term safety and efficacy evidence become available.

Insurance and Reimbursement Issues:

There might be variability in insurance coverage for NK treatments, with certain treatments not receiving any coverage at all. Patients may incur significant out-of-pocket costs as a result, further restricting their access to efficacious treatments.

Limited Research and Development:

Compared to more prevalent illnesses, there is comparatively less research and development activity because of the disease's rarity. This may impede the development of novel therapies and the advancement of current ones.

Economic Restrictions:

In low- and middle-income nations, financial restrictions may severely restrict access to cutting-edge NK treatments. The broad availability and usage of sophisticated medicines may be hindered by the inadequate healthcare infrastructure in these locations.

Patient Compliance:

Strict adherence to pharmaceutical regimens is often necessary for NK treatments, which might provide difficulties for patients. Non-compliance may result in less than ideal treatment results, which lowers the therapies' perceived efficacy.

Lack of Specialist Care:

Ophthalmologists with experience treating corneal illnesses are typically needed to treat neurotrophic keratitis. The lack of these specialists can be a major obstacle to providing quality care, particularly in poor and rural locations

Global Neurotrophic Keratitis Treatment Market Segmentation Analysis

The Global Neurotrophic Keratitis Treatment Market is segmented on the basis of Treatment and Geography.

Neurotrophic Keratitis Treatment Market, By Treatment

• Topical Antibiotics
• Recombinant Human Nerve Growth Factor (rhNGF)
• Amniotic Membrane Transplantation
• Keratoplasty
• Others

Based on Treatment, the market is bifurcated into Topical Antibiotics, Recombinant Human Nerve Growth Factor (rhNGF), Amniotic Membrane Transplantation, Keratoplasty, and Others. The dominance of topical antibiotics in the Neurotrophic Keratitis Treatment Market in the past few years can be attributed to several factors. Topical antibiotics are effective in managing neurotrophic keratitis because they have antimicrobial properties. Neurotrophic keratitis can make the cornea vulnerable to infections, and topical antibiotics help prevent or treat these infections, reducing the risk of complications.

• Topical antibiotics have been a conventional and widely used treatment approach for various corneal conditions, including neurotrophic keratitis. Healthcare professionals are familiar with their use, and readily available in numerous formulations, making them a preferred choice for initial treatment. Topical antibiotics often have a broad spectrum of action, targeting many bacteria that may cause corneal infections. This versatility makes them suitable for treating different bacterial infections associated with neurotrophic keratitis. Topical antibiotics are typically administered as eye drops or ointments, making them easy to apply.
• Patients can often self-administer these medications at home, which improves treatment compliance and convenience. The neurotrophic keratitis treatment landscape is constantly evolving. Emerging treatment options, such as recombinant human nerve growth factor (rhNGF), amniotic membrane transplantation, and keratoplasty, are gaining attention and showing promising results in clinical studies. While topical antibiotics have been dominant in the past, the market dynamics may shift as newer treatment modalities gain acceptance and demonstrate their efficacy in managing neurotrophic keratitis. Therefore, monitoring the latest developments and research findings is essential to stay updated on the evolving treatment landscape.

Neurotrophic Keratitis Treatment Market, By Geography

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa
• On the basis of Geography, the Global Neurotrophic Keratitis Treatment Market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. The Neurotrophic Keratitis Treatment Market has been identified as having high growth potential in the Asia Pacific area. The Asia Pacific region has the largest population, including a growing elderly population. Neurotrophic keratitis is more prevalent among the elderly, and as the population ages over time, the demand for neurotrophic keratitis treatment is expected to increase.
• Many major countries in the Asia Pacific region are experiencing rapid economic growth and increasing healthcare expenditure. This provides greater accessibility to healthcare services, including neurotrophic keratitis treatment, and drives market growth. Several other countries in the Asia Pacific region have been investing in improving their healthcare infrastructure. This includes the development of specialized eye care centers, advanced medical facilities, and increased availability of treatment options, which contribute to the growth of the Neurotrophic Keratitis Treatment Market.

Key Players

• The major players in the Neurotrophic Keratitis Treatment Market are
• Santen Pharmaceutical Co. Ltd.
• Novartis AG
• RegeneRx
• Biopharmaceuticals Inc.
• Dompe farmaceutici S.p.A.
• Dompe Farma S.r.l.
• Horizon Therapeutics plc
• AuroLab
• Genentech Inc. (a subsidiary of Roche Holding AG)
• Johnson & Johnson Services Inc.
• Allergan (a subsidiary of AbbVie Inc.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL NEUROTROPHIC KERATITIS TREATMENT MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL NEUROTROPHIC KERATITIS TREATMENT MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL NEUROTROPHIC KERATITIS TREATMENT MARKET, BY TREATMENT

• 5.1 Topical Antibiotics
• 5.2Recombinant Human Nerve Growth Factor (rhNGF)
• 5.3Amniotic Membrane Transplantation
• 5.4Keratoplasty
• 5.5Others

6 GLOBAL EUROTROPHIC KERATITIS TREATMENT MARKET, BY GEOGRAPHY

• 6.1 Overview
• 6.2 North America
  • 6.2.1 U.S.
  • 6.2.2 Canada
  • 6.2.3 Mexico
• 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 U.K.
  • 6.3.3 France
  • 6.3.4 Rest of Europe
• 6.4 Asia Pacific
  • 6.4.1 China
  • 6.4.2 Japan
  • 6.4.3 India
  • 6.4.4 Rest of Asia Pacific
• 6.5 Rest of the World
  • 6.5.1 Latin America
  • 6.5.2 Middle East & Africa

7 GLOBAL NEUROTROPHIC KERATITIS TREATMENT MARKET COMPETITIVE LANDSCAPE

• 7.1 Overview
• 7.2 Company Market Ranking
• 7.3 Key Development Strategies

8 COMPANY PROFILES

• 8.1 Santen Pharmaceutical Co. Ltd.
• 8.1 Novartis AG
• 8.2 RegeneRx
• 8.3 Biopharmaceuticals Inc.
• 8.4 Dompe farmaceutici S.p.A.
• 8.5 Dompe Farma S.r.l.
• 8.6 Horizon Therapeutics plc
• 8.7 AuroLab
• 8.8 Genentech Inc. (a subsidiary of Roche Holding AG)
• 8.9 Johnson & Johnson Services Inc.
• 8.10 Allergan (a subsidiary of AbbVie Inc.

9 Appendix

• 9.1 Related Research